Most importantly, novel inhibitors of PHDs, specifically PHD2 inhibitors, markedly intensify the nuclear expression of HIF-2α in EPO-producing peritubular cells located in the deep cortex [10], and are now approved for use as EPO inducers in patients with advanced chronic kidney disease [18]. Here, EPO is linked to chronic kidney disease.